tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000943819 /10-K filed Aug 13, 2026, compared with Aug 8, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
WATDXCMRMDEWSTEINCY
NYSE, OTC Health care · Medical Instruments

ResMed RMD

RMD quote by TradingView

We are a global leader in digital health and cloud-connected medical devices. 10-K, Item 1

Employees
11,370
Headquarters
San Diego, CA
CEO
Michael J. Farrell
Next results
around Jan 28, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2026

Revenue of $5.7B through the costs to a net profit of $1.5B · income statement of the 10-K

33% operating margin
Revenue to Gross profit: $3.5BRevenue to Cost of revenue: $2.2BGross profit to Operating profit: $1.9BGross profit to Operating expenses: $1.6BOperating profit to Net profit: $1.5BOperating profit to Tax & other: $363.4MOperating expenses to R&D: $378.3MOperating expenses to Sales, admin & other: $1.2B Revenue: $5.7B REVENUE $5.7B +10% Y/Y Gross profit: $3.5B · 61% margin GROSS PROFIT $3.5B 61% margin · +13% Y/Y Cost of revenue: $2.2B · 39% of revenue COST OF REVENUE $2.2B 39% of revenue Operating profit: $1.9B · 33% margin OPERATING PROFIT $1.9B 33% margin · +12% Y/Y Operating expenses: $1.6B · 28% of revenue OPERATING EXPENSES $1.6B 28% of revenue Net profit: $1.5B · 27% margin NET PROFIT $1.5B 27% margin · +9% Y/Y Tax & other: $363.4M · 6% of revenue TAX & OTHER $363.4M 6% of revenue R&D: $378.3M · 7% of revenue R&D $378.3M 7% of revenue Sales, admin & other: $1.2B · 21% of revenue SALES, ADMIN & OTHER $1.2B 21% of revenue
Gross profit $3.5B 61% margin · +13% Y/Y
Operating profit $1.9B 33% margin · +12% Y/Y
Net profit $1.5B 27% margin · +9% Y/Y
The full income statement, year by year

RMD among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 9.9%, above 68% of 59 peers (their median 7.1%) REVENUE GROWTH 9.9% · above 68% Gross margin: 61.1%, above 44% of 50 peers (their median 65.2%) GROSS MARGIN 61.1% · above 44% Operating margin: 33.0%, above 98% of 50 peers (their median 13.4%) OPERATING MARGIN 33.0% · above 98% Net margin: 27.8%, above 93% of 59 peers (their median 9.5%) NET MARGIN 27.8% · above 93% FCF margin: 28.1%, above 95% of 55 peers (their median 15.2%) FCF MARGIN 28.1% · above 95% Return on capital: 23.6%, above 95% of 41 peers (their median 9.0%) RETURN ON CAPITAL 23.6% · above 95%
RMD Peer median Below the median

What changed

17 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Aug 13, 2026 against Aug 8, 2025.

Risk factors
17 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Auditor change
8-K item 4.01 (change in certifying accountant) filed Aug 17, 2026
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
6 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Auditor change
    8-K item 4.01 (change in certifying accountant) filed Aug 17, 2026
  • Receivables +10.3% vs revenue +9.9% (+0.4 pts)
9 more checks with nothing to note
  • Cash from operations $1.8B vs net income $1.5B (FY ending Jun 30, 2026)
  • Inventory +2.0% vs revenue +9.9% (-7.9 pts)
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Evaluation of goodwill triggering events; PART II Item 8; RESMED INC. AND SUBSIDIARIES
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

17 paragraphs in Risk Factors that were not in the 10-K filed Aug 8, 2025. Quoted as filed.

All 17 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Aug 8, 2025 10-K, ITEM 1A
    We are subject to new areas of direct healthcare oversight by federal government agencies due to our acquisitions of VirtuOx and Noctrix. In 2025, we acquired VirtuOx, a software-enabled independent diagnostic testing facility, or IDTF, and provider of technology solutions to facilitate in-home and remote testing services for sleep,…
  2. Item 1A · new paragraph · not in the 10-K filed Aug 8, 2025 10-K, ITEM 1A
    Failure to identify, execute, and integrate acquired businesses into our operations successfully, or challenges related to the Company's strategic initiatives, including divestitures. As part of our strategy to develop and identify new solutions and technologies and optimize our portfolio of products, we have completed several…
  3. Item 1A · new paragraph · not in the 10-K filed Aug 8, 2025 10-K, ITEM 1A
    Further, if we fail to innovate or adequately invest in new technologies, we could lose our competitive position in the markets that we serve. To the extent that we fail to introduce new and innovative products, or such products are not accepted or suffer significant delays in development, our financial results may suffer. An inability,…
  4. Item 1A · new paragraph · not in the 10-K filed Aug 8, 2025 10-K, ITEM 1A
    On June 9, 2025, CMS finalized a National Coverage Determination (NCD) entitled “Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure (CRF) Consequent to Chronic Obstructive Pulmonary Disease (COPD).” The NCD establishes a uniform national coverage criteria for Respiratory Assist…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2023FY2024FY2025FY2026
Revenue$4.2B$4.7B$5.1B$5.7B
Net income$897.6M$1.0B$1.4B$1.5B
Operating cash flow$693.3M$1.4B$1.8B$1.8B
Free cash flow$573.6M$1.3B$1.7B$1.6B

Revenue, FY2017 to FY2026

Ten fiscal years, each from its own 10-K · XBRL · USD

$5.7B ▲ 9.9% in FY2026

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Every number, year by year

Recent filings

6 filings in the last 30 days · SEC EDGAR

All filings
1 more

About the company

ResMed, San Diego, CA · from the 10-K filed Aug 13, 2026

We are a global leader in digital health and cloud-connected medical devices. We design innovative technology to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.

Headquarters
San Diego, CA
Country
United States
Reports in
USD
Listed on
NYSE, OTC
Fiscal year ends
June 30
Last results
Oct 29, 2026
Incorporated in
DE

Employees, at the top of the page: "We employ approximately 11,370 people and sell our products in more than 140 countries through a combination of wholly owned subsidiaries and independent distributors" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Aug 13, 2026 (open at SEC), compared with the 10-K filed Aug 8, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RMD/export.csv") into a cell.